Affinity Asset Advisors, LLC — 13F Holdings & Portfolio
CIK 1773195 · latest 13F-HR filed 2026-08-13
Affinity Asset Advisors, LLC manages $2.21B in 13F-reported U.S. long-equity assets across 113 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ROIV (6.00%), APGE (5.92%), SYRE (5.13%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 19 new positions, exited 10, added to 56, and trimmed 21.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 1403
NEW YORK, NY 10022
$2.21B
Long-equity book
113
Distinct positions
2026-06-30
Filed 2026-08-13
+19 / −10 / ↑56 / ↓21
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ROIVANT SCIENCES LTD$55.2M +71.1%
- SPYRE THERAPEUTICS INC$49.0M +76.0%
- REVOLUTION MEDICINES INC$37.1M +381.4%
- AVALO THERAPEUTICS INC$33.6M +167.7%
- ORUKA THERAPEUTICS INC$31.6M +129.1%
Top Trims
- TEVA PHARMACEUTICAL INDS LTD-$29.5M -70.0%
- COGENT BIOSCIENCES INC-$11.5M -39.7%
- INSMED INC-$9.2M -11.7%
- MADRIGAL PHARMACEUTICALS INC-$7.3M -25.4%
- ZURA BIO LTD-$6.6M -43.4%
New Positions
- FIRST TRACKS BIOTHERAPEUTICS$40.9M
- IDEAYA BIOSCIENCES INC$14.9M
- ODYSSEY THERAPEUTICS INC$14.3M
- UNIQURE NV$8.1M
- ASCENDIS PHARMA A/S$8.0M
Exited Positions
- CENTESSA PHARMACEUTICALS PLC$55.6M
- ARCELLX INC$41.7M
- TERNS PHARMACEUTICALS INC$29.7M
- ASCENDIS PHARMA A/S$21.7M
- BRIDGEBIO PHARMA INC$11.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $132.7M | 6.00% | 3,750,000 | SH |
| 2 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $131.0M | 5.92% | 987,000 | SH |
| 3 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $113.6M | 5.13% | 1,279,134 | SH |
| 4 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $96.3M | 4.35% | 1,595,000 | SH |
| 5 | ERASCA INC | ERAS | 29479A108 | $96.2M | 4.35% | 5,250,000 | SH |
| 6 | INSMED INC | INSM | 457669307 | $69.3M | 3.13% | 650,000 | SH |
| 7 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $61.9M | 2.80% | 185,000 | SH |
| 8 | ALKERMES PLC | ALKS | G01767105 | $58.9M | 2.66% | 1,125,000 | SH |
| 9 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $56.2M | 2.54% | 590,000 | SH |
| 10 | ANAPTYSBIO INC | ANAB | 032724106 | $55.8M | 2.52% | 826,109 | SH |
| 11 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $53.6M | 2.42% | 2,900,000 | SH |
| 12 | CYTOKINETICS INC | CYTK | 23282W605 | $46.9M | 2.12% | 550,000 | SH |
| 13 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $46.8M | 2.12% | 250,000 | SH |
| 14 | ABIVAX SA | ABVX | 00370M103 | $44.0M | 1.99% | 330,000 | SH |
| 15 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $40.9M | 1.85% | 2,032,012 | SH |
| 16 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $39.0M | 1.76% | 400,000 | SH |
| 17 | SUTRO BIOPHARMA INC | STRO | 869367201 | $38.9M | 1.76% | 1,172,487 | SH |
| 18 | MODERNA INC Put | MRNA | 60770K107 | $35.0M | 1.58% | 500,000 | SH |
| 19 | NUVALENT INC | NUVL | 670703107 | $34.0M | 1.54% | 275,000 | SH |
| 20 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $33.6M | 1.52% | 1,800,172 | SH |
| 21 | MODERNA INC Call | MRNA | 60770K107 | $33.3M | 1.50% | 475,000 | SH |
| 22 | ARK ETF TR Call | ARKG | 00214Q302 | $31.5M | 1.43% | 750,000 | SH |
| 23 | OVID THERAPEUTICS INC | OVID | 690469101 | $27.3M | 1.23% | 10,144,562 | SH |
| 24 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $27.0M | 1.22% | 5,807,611 | SH |
| 25 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $26.0M | 1.18% | 700,000 | SH |
| 26 | BELITE BIO INC | BLTE | 07782B104 | $25.4M | 1.15% | 165,000 | SH |
| 27 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $25.4M | 1.15% | 500,000 | SH |
| 28 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $24.3M | 1.10% | 1,145,391 | SH |
| 29 | ELI LILLY & CO Call | LLY | 532457108 | $24.0M | 1.08% | 20,000 | SH |
| 30 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $23.5M | 1.06% | 967,620 | SH |
| 31 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $22.4M | 1.01% | 850,000 | SH |
| 32 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $21.5M | 0.97% | 40,000 | SH |
| 33 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $21.1M | 0.95% | 172,125 | SH |
| 34 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $20.2M | 0.91% | 750,000 | SH |
| 35 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $19.6M | 0.89% | 1,050,000 | SH |
| 36 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $19.3M | 0.87% | 2,497,864 | SH |
| 37 | JADE BIOSCIENCES INC | JBIO | 008064206 | $18.7M | 0.84% | 840,350 | SH |
| 38 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $17.4M | 0.79% | 450,000 | SH |
| 39 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $17.0M | 0.77% | 300,000 | SH |
| 40 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $15.9M | 0.72% | 875,760 | SH |
| 41 | SAVARA INC | SVRA | 805111101 | $15.5M | 0.70% | 2,512,153 | SH |
| 42 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $14.9M | 0.67% | 400,000 | SH |
| 43 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $14.4M | 0.65% | 4,214,582 | SH |
| 44 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $14.3M | 0.65% | 766,346 | SH |
| 45 | COGENT BIOSCIENCES INC | COGT | 19240QAA0 | $13.7M | 0.62% | 11,000,000 | PRN |
| 46 | OMEROS CORP Put | OMER | 682143102 | $13.4M | 0.61% | 1,411,300 | SH |
| 47 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $13.3M | 0.60% | 1,250,000 | SH |
| 48 | EQUILLIUM INC | EQ | 29446K106 | $13.1M | 0.59% | 4,100,000 | SH |
| 49 | ALKERMES PLC Call | ALKS | G01767105 | $13.1M | 0.59% | 250,000 | SH |
| 50 | ESTABLISHMENT LABS HLDGS INC | ESTA | G31249108 | $12.7M | 0.57% | 148,013 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $2.21B | 113 | 0001011438-26-000516 |
| 2026-03-31 | 2026-05-14 | $1.94B | 105 | 0001315863-26-000411 |
| 2025-12-31 | 2026-02-13 | $1.76B | 95 | 0001315863-26-000153 |
| 2025-09-30 | 2025-11-13 | $1.15B | 96 | 0001999371-25-017685 |